Silvio Danese* and Gionata Fiorino Pages 280 - 287 ( 8 )
Biosimilars of infliximab (CT-P13) are currently approved and available for the same indications as for the originator. Some concerns about safety and immunogenicity have risen in the past because of lack of data in IBD. Since 2015, several cohort studies have been conducted in IBD showing that CT-P13 has comparable safety and efficacy profile to the originator, both in adult and pediatric population, either in naïve patients or even in those who switched from the originator to CT-P13. This review aims to analyze the current literature data in order to define a clear patient profile, to identify those IBD patients who would benefit the most from the use of CT-P13.
Infliximab, biosimilar, CT-P13, inflammatory bowel disease, Crohn’s disease, ulcerative colitis.
IBD Center, Department of Gastroenterology, Humanitas Research Hospital, Rozzano, Milan, IBD Center, Department of Gastroenterology, Humanitas Research Hospital, Rozzano, Milan